Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $3.8 million.

  • Ligand Pharmaceuticals' Cost of Revenue rose 5520.62% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 4571.78%. This contributed to the annual value of $11.1 million for FY2024, which is 534.63% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Cost of Revenue of $3.8 million as of Q3 2025, which was up 5520.62% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Cost of Revenue ranged from a high of $30.6 million in Q2 2021 and a low of $1.6 million during Q4 2023
  • Over the past 5 years, Ligand Pharmaceuticals' median Cost of Revenue value was $3.8 million (recorded in 2025), while the average stood at $7.8 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Cost of Revenue surged by 30022.24% in 2021 and then tumbled by 9240.77% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Cost of Revenue (Quarter) stood at $12.0 million in 2021, then skyrocketed by 80.36% to $21.6 million in 2022, then tumbled by 92.41% to $1.6 million in 2023, then soared by 72.88% to $2.8 million in 2024, then soared by 33.98% to $3.8 million in 2025.
  • Its Cost of Revenue was $3.8 million in Q3 2025, compared to $2.9 million in Q2 2025 and $4.8 million in Q1 2025.